Reunion Neuroscience Executives

REUNDelisted Stock  USD 1.12  0.01  0.90%   
Reunion Neuroscience employs about 16 people. The company is managed by 10 executives with a total tenure of roughly 38 years, averaging almost 3.0 years of service per executive, having 1.6 employees per reported executive. Analysis of Reunion Neuroscience's management performance can provide insight into the firm performance.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

Reunion Neuroscience Management Team Effectiveness

The company has return on total asset (ROA) of (0.2651) % which means that it has lost $0.2651 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8635) %, meaning that it created substantial loss on money invested by shareholders. Reunion Neuroscience's management efficiency ratios could be used to measure how well Reunion Neuroscience manages its routine affairs as well as how well it operates its assets and liabilities.

Reunion Neuroscience Workforce Comparison

Reunion Neuroscience is rated fourth in number of employees category among its peers. The total workforce of Biotechnology industry is at this time estimated at about 1,541. Reunion Neuroscience claims roughly 16.0 in number of employees contributing just under 2% to stocks in Biotechnology industry.

Reunion Neuroscience Notable Stakeholders

A Reunion Neuroscience stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Reunion Neuroscience often face trade-offs trying to please all of them. Reunion Neuroscience's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Reunion Neuroscience's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
MD MBAVP DirectorProfile
Nathan BScChief OfficerProfile
Stephan CoteHead QualityProfile
Hannan FleimanCoFounder DirectorProfile
Mujeeb JafferiCOFounder COOProfile
Edward CPAChief OfficerProfile
Vicki ReedChief OfficerProfile
Curtis WeberGen SecProfile
JD EsqCEO PresProfile
Matt EmmerDirector DevelProfile

About Reunion Neuroscience Management Performance

The success or failure of an entity such as Reunion Neuroscience often depends on how effective the management is. Reunion Neuroscience management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Reunion management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Reunion management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. Field Trip Health Ltd. was founded in 2008 and is headquartered in Toronto, Canada. Reunion Neuroscience operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 194 people.

Reunion Neuroscience Workforce Analysis

Traditionally, organizations such as Reunion Neuroscience use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Reunion Neuroscience within its industry.

Reunion Neuroscience Manpower Efficiency

Return on Reunion Neuroscience Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee3M
Net Loss Per Executive4.8M
Working Capital Per Employee1.3M
Working Capital Per Executive2.1M
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

Other Consideration for investing in Reunion Stock

If you are still planning to invest in Reunion Neuroscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reunion Neuroscience's history and understand the potential risks before investing.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation